Preclinical Evaluation of (203/212)Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer

Targeted radiopharmaceutical therapy (TRT) using α-particle radiation is a promising approach for treating both large and micrometastatic lesions. We developed prostate-specific membrane antigen (PSMA)–targeted low-molecular-weight agents for (212)Pb-based TRT of patients with prostate cancer (PC) b...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Nucl Med
Auteurs principaux: Banerjee, Sangeeta Ray, Minn, Il, Kumar, Vivek, Josefsson, Anders, Lisok, Ala, Brummet, Mary, Chen, Jian, Kiess, Ana P., Baidoo, Kwamena, Brayton, Cory, Mease, Ronnie C., Brechbiel, Martin, Sgouros, George, Hobbs, Robert F., Pomper, Martin G.
Format: Artigo
Langue:Inglês
Publié: Society of Nuclear Medicine 2020
Sujets:
Theranostics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6954458/
https://ncbi.nlm.nih.gov/pubmed/31253744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.119.229393
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires